NEW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A. (Nasdaq:
GENT) announced the presentation of both clinical and preclinical
data that support the safety, activity, synergy and potential
mechanism of action of Defibrotide in combination with anticancer
therapy in multiple myeloma. Investigators presented both an update
from the Company's ongoing Phase I/II clinical trial for patients
with refractory or relapsed multiple myeloma with Defibrotide in
combination with chemotherapy, as well as a pre-clinical study
demonstrating the downregulation of a key regulatory enzyme
supporting a novel mechanism of action for Defibrotide in myeloma.
Data from both studies was presented at the XI International
Myeloma Workshop in Kos, Greece, 25-30 June, 2007.

In the first study, investigators led by Dr Antonio Palumbo of
The Italian Multiple Myeloma Study Group, presented data from an
ongoing multi-center, phase I/II clinical trial for relapsed or
refractory multiple myeloma patients. This study is being conducted
in an effort to define the maximum tolerated dose (MTD), safety and
potential efficacy of the combination of melphalan, prednisone,
thalidomide and Defibrotide (MPTD). Nineteen patients, who received
at least three cycles of MPTD were evaluable for toxicity and
response. Three escalating dose levels of Defibrotide were
evaluated in combination with standard doses of melphalan,
prednisone and thalidomide. No other thromboprophylaxis was
administered. After a median of 3 cycles, the major response rate,
including complete and partial remission was 53% (1CR, 1nCR and
7PR). Responses were seen in all three Defibrotide dose levels.
Follow up remains limited and the durability of response appears
favorable. MTD was not reached in any cohort. Hematological
toxicities (greater than/equal to Grade 3) included neutropenia
(47%), thrombocytopenia (10%), anemia (21%), non-hematological
toxicities greater than/equal to grade 3 were observed in less than
5% of patients. Impor
tantly only one DVT has been seen to date and
no significant peripheral neuropathy has been reported.

In a preclinical study presented by Dr. Cinara Echart, Gentium's
Manager of Molecular Biology, at the same meeting, Defibrotide
demonstrated the ability to significantly downregulate heparanase
gene expression and activity in myeloma cell lines in a dose
dependent manner (p less than 0.01). In addition, Defibrotide
decreases the myeloma cell invasion through the Matrigel matrix in
vitro by 50%. Elevated heparanase expression in humans has been
correlated with advanced progression and metastasis of many tumor
types, including myeloma. Heparanase acts as a key mechanism for
breakdown of extracellular matrix to facilitate tumor invasion and
metastasis.

Dr. Antonio Palumbo commented, "The combination of MPTD is
promising both in terms of activity and tolerability with the low
rate of DVT being especially interesting. Moreover, the preclinical
studies with Defibrotide are intriguing, suggesting a wider role
for this drug as an orally biovavailable agent in combination with
chemotherapy as a potential treatment for multiple myeloma."

About Gentium

Gentium, S.p.A., located in Como, Italy, is a biopharmaceutical
company focused on the research, development and manufacture of
drugs to treat and prevent a variety of vascular diseases and
conditions related to cancer and cancer treatments. Defibrotide,
the Company's lead product candidate, is an investigational drug
that has been granted a Fast Track Designation by the U.S. FDA to
treat Severe VOD in recipients of stem cell transplants, Orphan
Drug status by the U.S. FDA to treat and prevent VOD and Orphan
Medicinal Product Designation by the European Commission to treat
and prevent VOD.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements." In
some cases, you can identify these
statements by forward-looking
words such as "may," "might," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential" or
"continue," the negative of these terms and other comparable
terminology. These statements are not historical facts but instead
represent the Company's belief regarding future results, many of
which, by their nature, are inherently uncertain and outside the
Company's control. It is possible that actual results may differ,
possibly materially, from those anticipated in these
forward-looking statements. For a discussion of some of the risks
and important factors that could affect future results, see the
discussion in our Form 20F filed with the Securities and Exchange
Commission under the caption "Risk Factors."

(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it had joined the Pharmaceutical Supply Chain ... organization to unite pharmaceutical and healthcare companies that share a vision of better, ...